Search Results

Displaying Results 251-275 of 17441 "'NOV'"

May 27, 2026, 02:28 ET Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018 Nov;18(11):2752-2762. doi: 10.1111/ajt.14733.NIH (2018). What is kidney failure? Available at:

More news about: Hansa Biopharma AB


May 27, 2026, 02:25 ET Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018 Nov;18(11):2752-2762. doi: 10.1111/ajt.14733.NIH (2018). What is kidney failure? Available at:

More news about: Hansa Biopharma AB


May 26, 2026, 08:08 ET Sportradar Group AG (SRAD) Securities Class Action Filed Amid Activist Short Seller Accusations of Illegal Business Model and $800 Million Market Cap Wipeout - Hagens Berman

now. The firm also encourages persons with knowledge who may be able to assist the investigation to contact its attorneys.Class Period: Nov. 7, 2024 – Apr. 21, 2026Lead Plaintiff Deadline: July 17, 2026Visit:

More news about: Hagens Berman Sobol Shapiro LLP


May 25, 2026, 22:53 ET Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026

pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018 Nov;18(11):2752-2762. doi: 10.1111/ajt.14733.NIH (2018). What is kidney failure? Available at:

More news about: Hansa Biopharma AB


May 25, 2026, 22:52 ET Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026

pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018 Nov;18(11):2752-2762. doi: 10.1111/ajt.14733.NIH (2018). What is kidney failure? Available at:

More news about: Hansa Biopharma AB


May 25, 2026, 12:40 ET Redefining Kids Content: Mindiful®'s The Moon Show Blends Storytelling and Mindfulness for Every Kid

Brad. "We don't have a classroom management problem. We have a youth mental-health crisis that teachers are being asked to handle…" Facebook, 30 Nov. 2025.3. Dabrowski A, Hsien M, Van Der Zant T and Ahmed SK (2025) "We are left to fend for ourselves": understanding why teachers struggle to

More news about: Mindiful


May 25, 2026, 08:45 ET A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia

Prevalence of Familial Hypercholesterolemia and Its Association with Cardiovascular Risk in a Cross-Sectional Adult Population. J Clin Med. 2025 Nov 19;14(22):8213. doi: 10.3390/jcm14228213.3. Stark, B., et al. Global Prevalence of Coronary Artery Disease: An Update from the Global Burden

More news about: Eli Lilly and Company


May 21, 2026, 17:00 ET Sapience Therapeutics Provides Positive Data Update from Phase 2 Trial of Lucicebtide Plus SOC in Patients with Glioblastoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Mason JM, Merutka G, Kappel BJ, Rotolo JA. Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β. Mol Cancer Ther. 2022 Nov 3;21(11):1632-1644. doi: 10.1158/1535-7163.MCT-21-0962. PMID: 36121385; PMCID: PMC9630826.

More news about: Sapience Therapeutics, Inc.


May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting

impairment.Retevmo (selpercatinib) is available as 40 mg and 80 mg capsules, and 40 mg, 80 mg, 120 mg, and 160 mg tablets.SE HCP ISI LA_NOV2025Please see full 

More news about: Eli Lilly and Company


May 21, 2026, 10:05 ET Martha Raddatz, ABC News chief global affairs correspondent and "This Week" co-anchor, to accept National Press Club's highest honor

chief global affairs correspondent and "This Week" co-anchor, will accept the National Press Club's Fourth Estate Award during a gala in her honor on Nov. 12 in Washington, D.C. Over her decades-long career, Raddatz has covered national security, foreign policy, and politics from the State Department,

More news about: National Press Club


May 21, 2026, 09:00 ET Sportradar Group AG (SRAD) Securities Class Action Filed Amid Activist Short Seller Accusations of Illegal Business Model and $800 Million Market Cap Wipeout - HBSS

now. The firm also encourages persons with knowledge who may be able to assist the investigation to contact its attorneys.Class Period: Nov. 7, 2024 – Apr. 21, 2026Lead Plaintiff Deadline: July 17, 2026Visit:

More news about: Hagens Berman Sobol Shapiro LLP


May 21, 2026, 08:23 ET Scientific Longevity Company Immorta Bio Appoints Former Ernst & Young Health Sciences Partner Howard Brooks to Corporate Board of Directors

[email protected] 1 Ichim et al. Reduction of solid tumors by senescent cell immunization. J Transl Med. 2025 Nov 28;23(1):1365.

More news about: Immorta Bio Inc.


May 20, 2026, 13:30 ET SITC Announces Keynote Speakers Dr. Ton Schumacher and Dr. Catherine J. Wu at its 41st Annual Meeting

www.sitcancer.org/2026 for the latest updates and to register for SITC's 41st Annual Meeting & Pre-Conference Programs, being held from Nov. 4–8, 2026, at the Phoenix Convention Center, Phoenix, AZ. Virtual participation is also available. Visit

More news about: Society for Immunotherapy of Cancer (SITC)


May 20, 2026, 03:00 ET Greenberg Traurig's Capital Markets Practice Recognized Across Five Winning Deals of the Year at Islamic Finance News Awards 2025

and the popularity of these instruments reaches new markets," Roussos said.The IFN Awards follow on from the IFN KSA Dialogues 2025 event on Nov. 19, 2025, where Ahmed and Roussos featured as panellists discussing "Shaping the Future: Islamic Investment Products and Asset Management in Saudi Arabia"

More news about: Greenberg Traurig, LLP


May 19, 2026, 15:14 ET BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data

efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ann Rheum Dis. 2023 Nov;82(11):1404-1414.Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, et al. American

More news about: UCB


May 19, 2026, 06:31 ET FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

strategies for heavily calcified coronary stenoses: an EAPCI clinical consensus statement in collaboration with the EURO4C-PCR group. Eur Heart J. Nov 1 2023;44(41):4340-4356. doi:10.1093/eurheartj/ehad342 2 Räber L, Mintz GS, Koskinas KC, Johnson TW, Holm NR, Onuma Y, Radu MD, Joner

More news about: Boston Scientific Corporation


May 19, 2026, 02:23 ET Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA

pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018 Nov;18(11):2752-2762. doi: 10.1111/ajt.14733.NIH (2018). What is kidney failure? Available at:

More news about: Hansa Biopharma AB


May 19, 2026, 02:20 ET Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA

pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018 Nov;18(11):2752-2762. doi: 10.1111/ajt.14733.NIH (2018). What is kidney failure? Available at:

More news about: Hansa Biopharma AB


May 18, 2026, 12:21 ET COTY 4-DAY DEADLINE ALERT: Coty Inc. (COTY) Investors Face Losses Following Company Allegedly Concealed Deteriorating Trends: Hagens Berman

youtu.be/jQoWASUHcgIClass Period: Nov. 5, 2025 – Feb. 4, 2026Lead Plaintiff Deadline: May 22, 2026Visit:

More news about: Hagens Berman Sobol Shapiro LLP


May 15, 2026, 09:00 ET CONSULTING MAGAZINE OPENS NOMINATIONS FOR 2026 WOMEN LEADERS IN CONSULTING AWARDS

for the 2026 awards will be accepted until July 31, 2026. The 2026 honorees will be officially recognized and celebrated at a special awards gala on Nov. 19, 2026, at the New York Marriott Marquis Times Square.For complete details on the nomination criteria visit

More news about: Consulting Magazine


May 14, 2026, 14:22 ET COTY 8-DAY DEADLINE ALERT: Coty Inc. (COTY) Investors Face Losses Following Company Allegedly Concealed Deteriorating Trends: Hagens Berman

youtu.be/jQoWASUHcgIClass Period: Nov. 5, 2025 – Feb. 4, 2026Lead Plaintiff Deadline: May 22, 2026Visit:

More news about: Hagens Berman Sobol Shapiro LLP


May 14, 2026, 09:00 ET Global Traveler Announces Hosted Cruise on Brand-New Transcend Cruises

for luxury travelers, invites subscribers and friends to join CEO and publisher Francis X. Gallagher for an experience along the Rhine River, Oct. 29–Nov. 5, on brand-new Transcend Cruises, a charter-only, buyout river cruise company whose state-of-the-art fleet is purpose-built for meetings and events.

More news about: Global Traveler


May 13, 2026, 10:58 ET DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates

(filed Apr. 29, 2025).20 See Pacira BioSciences Press Releases (Apr. 8, 2026, Mar. 6, 2026, Feb. 9, 2026, Jan. 8, 2026, Dec. 3, 2025, Nov. 6, 2025, Oct. 3, 2025, Sep. 5, 2025, Aug. 5, 2025, Jul. 3, 2025, Jun. 5, 2025, May 8, 2025, Apr. 11, 2025, Mar. 6, 2025, Feb. 6, 2025, and Jan. 10,

More news about: DOMA Perpetual


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.